about
Insights into Neuroinflammation in Parkinson's Disease: From Biomarkers to Anti-Inflammatory Based TherapiesNeuroimmunology of Huntington's Disease: Revisiting Evidence from Human StudiesMonocyte and lymphocyte activation in bipolar disorder: a new piece in the puzzle of immune dysfunction in mood disorders.Urinary Levels of IL-1β and GDNF in Preterm Neonates as Potential Biomarkers of Motor Development: A Prospective Study.Cognitive Status Correlates with CXCL10/IP-10 Levels in Parkinson's Disease.Is there any association between Toxoplasma gondii infection and bipolar disorder? A systematic review and meta-analysis.Further evidence for an anti-inflammatory role of artesunate in experimental cerebral malariaSerum levels of neurotrophic factors in active toxoplasmic retinochoroiditis.Immunomodulatory strategies for Huntington's disease treatment.Reduced Activated T Lymphocytes (CD4+CD25+) and Plasma Levels of Cytokines in Parkinson's Disease.Moving from the Dish to the Clinical Practice: A Decade of Lessons and Perspectives from the Pre-Clinical and Clinical Stem Cell Studies for Alzheimer's Disease.The Anti-Inflammatory Potential of ACE2/Angiotensin-(1-7)/Mas Receptor Axis: Evidence from Basic and Clinical Research.Migraine is associated with altered levels of neurotrophins.Absence of gut microbiota influences lipopolysaccharide-induced behavioral changes in mice.Circulating levels of neurotrophic factors in autism spectrum disorders.A Neuroprotective Effect of the Glutamate Receptor Antagonist MK801 on Long-Term Cognitive and Behavioral Outcomes Secondary to Experimental Cerebral Malaria.Evidence for the contribution of adult neurogenesis and hippocampal cell death in experimental cerebral malaria cognitive outcome.Lower Cerebrospinal Fluid Concentration of Brain-Derived Neurotrophic Factor Predicts Progression from Mild Cognitive Impairment to Alzheimer's Disease.Renin angiotensin system in liver diseases: Friend or foe?Neurotrophic factors in obsessive-compulsive disorder.Circulating levels of GDNF in bipolar disorder.Early changes in adipokines from overweight to obesity in children and adolescents.Plasma Levels of Tumor Necrosis Factor Superfamily Molecules Are Increased in Bipolar Disorder.Anti-NMDAR antibodies as a new piece in schizophrenia's puzzle.Peripheral blood mono-nuclear cells derived from Alzheimer's disease patients show elevated baseline levels of secreted cytokines but resist stimulation with β-amyloid peptide.Promises and pitfalls of immune-based strategies for Huntington's disease.Revisiting the neuropsychiatry of Huntington's disease.Circulating levels of adipokines in Parkinson's disease.Changes in adipokine levels in autism spectrum disorders.Right hippocampus size is negatively correlated with leptin serum levels in bipolar disorder.Sleep quality is associated with the severity of clinical symptoms in Parkinson's disease.Neurotrophic factors in tension-type headache.Reduced serum levels of adiponectin in tension-type headache.Increased interictal serum levels of CXCL8/IL-8 and CCL3/MIP-1α in migraine.Cannabinoid receptors on peripheral leukocytes from patients with schizophrenia: Evidence for defective immunomodulatory mechanisms.Increased serum levels of adiponectin in migraine.IL-6 serum levels are elevated in Parkinson's disease patients with fatigue compared to patients without fatigue.Klotho dysfunction: A pathway linking the aging process to bipolar disorder?Serum levels of adiponectin, CCL3/MIP-1α, and CCL5/RANTES discriminate migraine from tension-type headache patients.Peripheral levels of angiotensins are associated with depressive symptoms in Parkinson's disease.
P50
Q26795984-6534C54B-CEA8-45D6-8AF4-41C994CCF16CQ28072237-0B780193-C768-48D8-B0DA-CD5D8D3B4154Q33359759-2ABBE217-6C8C-496E-A3FF-082E5D1CDB1EQ33695610-0B851F56-A1C7-49D8-A66D-65E660C48D1AQ34438204-7C736B0A-2BEC-4DCD-A231-64253263A186Q34545951-C670118B-C8F6-41FF-92F9-31F59893C1CBQ37306230-31DF3F2B-B4A3-45AD-B733-10E6259B018DQ38727058-7536A825-65FA-4A3A-BACA-305CDB055923Q38729567-FD342CCB-334A-44FB-A5C7-3B6CFF89A959Q38760072-0D094F0B-3EDC-4361-BE71-2590107F80B8Q38843840-003EE7D4-77E0-4639-A06F-2938D6499690Q38911736-D742CF23-58C0-4B7C-9FB0-794B9D3EE2AAQ38927118-005A19F4-5807-481D-A10E-AC347B513EB4Q38930600-7D0A1703-70F1-4EBA-8E2D-A33CF5B59508Q38951320-843615A4-78E3-4B4B-AF4E-64161C7D7CFFQ38966356-6B84A99E-BE65-4467-9AD1-FBAE8F686E64Q38966361-A6129F60-182C-415E-B30E-E9282673288BQ38988833-60400DD5-64A8-4DB6-8BDC-C58515B5EB3CQ39360840-1BC6D6D3-5BB2-46C8-839E-729373BF24D9Q39365909-EEEBE999-2DE5-4081-B96B-EE803306CAC5Q39494313-970801B8-9588-4210-92DC-B3261BCE9B46Q39508303-40FC46FB-BADD-436A-8BCF-80EA8A2FD818Q41474650-FAC2E9D7-5344-4582-B9EF-BB38C5B9627CQ42335282-C1BAACB3-E3DA-472C-A3A9-5D9A0C2FCEACQ42495497-95146666-A535-4D42-B11D-EB4885F664B0Q45305225-EBC2B6B3-A9A5-4674-A911-B16F139BB940Q45305909-B1E340AD-21FC-4995-8CC9-399633F5E222Q46100223-542558C8-5DC3-4805-9D9B-522CB5D65BC4Q46600437-EA7536B5-3FF8-48F4-AED6-3A29EAFE739DQ47356932-9AC67D22-24A4-4845-B581-C53851F282ABQ47656700-AFC7525D-325B-4A74-BCDB-14AE9CCA6F97Q47693484-589E25E8-4FC5-4802-96AE-A2239F7129A8Q47737243-5E40F4CD-F415-49BD-82FC-445E67BCCD4EQ47819665-AC6F20C1-2B5D-44FB-951C-C1D6D739CC99Q47844730-0E02962B-BC1F-4CC5-AAAC-2813F44514A9Q47876962-6540C256-B5E6-4CD2-B84D-D1B5C51D4E2EQ47904490-B20E80E3-1FEA-4212-9F4A-FC5BE7B9BEC5Q47955588-9D783E52-D91D-4C99-B569-98BC7CFEF8C1Q48044181-13D35ACD-1E11-4A1D-98EF-F48B2B2FD4C4Q48044890-CB960B44-1BE5-4A6E-9F85-F4F591AE0B7E
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Natalia Pessoa Rocha
@ast
Natalia Pessoa Rocha
@en
Natalia Pessoa Rocha
@es
Natalia Pessoa Rocha
@nl
type
label
Natalia Pessoa Rocha
@ast
Natalia Pessoa Rocha
@en
Natalia Pessoa Rocha
@es
Natalia Pessoa Rocha
@nl
prefLabel
Natalia Pessoa Rocha
@ast
Natalia Pessoa Rocha
@en
Natalia Pessoa Rocha
@es
Natalia Pessoa Rocha
@nl
P1053
S-4021-2018
P106
P1153
36461676500
P21
P31
P496
0000-0003-2616-8082